Broncus Holding Corporation, backed by Exome, launches public offering in Hong Kong
NEW YORK–(COMMERCIAL THREAD) – Exome Asset Management (“Exome”), an innovative asset management firm focused on investing in global healthcare public markets, today announced its participation as a key investor in the IPO of Broncus Holding Corporation (SEHK: 2216), a medical device company for the development of interventional pulmonology products based in Hangzhou, China. The IPO was valued at $ 1.26 billion and will be traded on the Hong Kong Stock Exchange (“HKEX”). Exome was also part of Broncus Holding Corporation’s Series D at the start of 2021.
Sam Isaly, Managing Partner and Chief Investment Officer of Exome Asset Management, said: “At Exome, we believe that the opportunities for technological advancement in pulmonology are as important as those already realized in cardiology. Exome is excited about our investment in Broncus, and we look forward to partnering with the company as they continue to discover and develop respiratory products that have the potential to impact patients around the world. . ”
Exome works to improve the world by bringing health capital to those who need it most. The company practices two active investment strategies: one which invests extensively in healthcare sub-sectors and geographies across the world, and another which is an investment fund specializing in healthcare with an emphasis on opportunities for public companies in emerging markets. The company has a long bias in companies that are broadly diversified by geographic region and by health sub-sector.
About Exome Asset Management
Exome Asset Management is an innovative asset management company focused on investing in public markets in the global healthcare sector, including pharmaceuticals, biotechnology, healthcare services and medical devices. Exome uses solid investment strategies and a philosophy developed by Samuel D. Isaly, who has spent most of his 45-year career focused on healthcare in developed and emerging markets. For more information, please visit www.exomeasset.com.